Ozempic vs. Mounjaro: Which Drug Preserves More Muscle?

You probably chose your GLP-1 drug to lose weight. The question most people don’t ask until they’re already on it: am I losing fat, or am I losing muscle?

The answer, based on the best available research, is: both — and the ratio matters more than most people realize. Approximately 20–40% of the weight lost on GLP-1 drugs comes from lean tissue, not fat. Over a full course of treatment, that can add up to a meaningful loss of muscle strength and functional capacity.

The comparison between semaglutide and tirzepatide on this specific question — which one is gentler on your muscle — is more complicated than a simple winner. The clinical trial data and the real-world data disagree. Here’s what both actually show.

What the Clinical Trials Found

STEP 1: Semaglutide (Ozempic/Wegovy)

The STEP 1 body composition substudy is the most-cited dataset for semaglutide. Over 68 weeks, participants lost an average of 15.3% of body weight. Of that weight loss, lean mass (measured by DXA scan) declined by approximately 9.7% in absolute terms — but because fat mass fell even faster (−19.3%), the proportion of lean mass actually increased slightly.

The headline interpretation: semaglutide reduces lean mass in absolute terms, but it preferentially removes fat. Roughly 35–40% of total weight lost was lean mass, with the rest fat.

(Wilding et al., NEJM 2021; body composition substudy: Journal of the Endocrine Society, 2021)

SURMOUNT-1: Tirzepatide (Mounjaro/Zepbound)

Tirzepatide, the newer dual GIP/GLP-1 agonist, drove substantially more total weight loss — an average of 21.3% of body weight over 72 weeks in the SURMOUNT-1 substudy. The body composition breakdown was notably different from semaglutide’s:

• Fat mass decreased by 33.9%
• Lean mass decreased by 10.9%
• Of total weight lost: approximately 25% lean mass, 75% fat mass

That 25-vs-75 split, compared to semaglutide’s roughly 35-40-vs-60-65 split, looked like a genuine advantage for tirzepatide on muscle preservation. Because tirzepatide also triggers the GIP receptor (which semaglutide does not), there was a plausible biological mechanism for better fat selectivity.

(Look et al., Diabetes, Obesity and Metabolism, 2025)

SURPASS-3 MRI: A Deeper Look at Muscle Quality

The SURPASS-3 MRI substudy, published in The Lancet Diabetes & Endocrinology in 2025, examined tirzepatide’s effects on muscle quality — not just mass — using MRI in people with type 2 diabetes. The results showed favorable shifts in body fat distribution (prominent visceral and liver fat loss), but also highlighted changes in muscle composition that warrant attention for long-term users.

(Tirzepatide and muscle composition changes, SURPASS-3 MRI, Lancet Diabetes Endocrinol, 2025)

What the Real-World Data Found — And Why It Contradicts the Trials

In April 2026, researchers published a large-scale real-world analysis of 670,422 first-episode GLP-1 users — 456,742 on semaglutide and 213,680 on tirzepatide — using body composition data extracted from electronic health records over 12 months.

The finding flipped the narrative:

Tirzepatide was associated with greater lean body mass loss than semaglutide at every time point measured — excess lean mass losses of 1.1% at 3 months, 1.5% at 6 months, 1.3% at 9 months, and 2.0% at 12 months compared to semaglutide.

A category the researchers called the “Depletive GLP-1 metabotype” — defined as more than 20% total body weight loss with more than 5% lean mass loss — was significantly more common with tirzepatide (10.3%) than semaglutide (6.7%).

The largest risk factors for greater lean mass loss on either drug were musculoskeletal pain (cervicalgia and knee pain) and reduced exercise tolerance — in other words, patients who couldn’t exercise lost the most muscle.

(medRxiv preprint, April 2026)

Important caveat: This is a preprint — not yet peer-reviewed. Real-world observational data carries inherent selection biases that clinical trials control for. The finding is significant and worth knowing, but it is not the final word.

How to Reconcile the Contradiction

The clinical trial data (tirzepatide looks better) and the real-world data (tirzepatide looks worse) are not necessarily in conflict. They may be measuring different things.

In clinical trials, participants are carefully monitored, often given nutritional guidance, and the patient population is selected. Tirzepatide’s greater total weight loss — driven by stronger appetite suppression — may pull more fat with it proportionally in controlled conditions.

In real-world practice, tirzepatide’s more aggressive appetite suppression likely leads to more severe caloric restriction, lower protein intake, and potentially less physical activity due to side effects — the exact conditions that accelerate muscle loss. The drug that causes you to eat 350 fewer calories per day doesn’t just help you lose more fat; it can also drive you deeper into the protein deficit that strips muscle.

Real-world surveys consistently show GLP-1 users fall well below recommended protein targets — a predictable consequence of severely suppressed appetite. At that level of restriction, muscle loss on any GLP-1 drug is almost guaranteed — and the more aggressive the appetite suppression, the worse the problem.

The practical implication: the drug choice matters less than the behaviors you pair with it.

The Protein Problem: Both Drugs, Same Gap

The 2025 joint consensus statement from four major U.S. medical societies set the protein target for adults during active weight loss at 1.2–1.6 grams per kilogram of body weight per day. For a 180-pound (82 kg) person, that is 98–131 grams of protein daily.

The average GLP-1 user in real-world surveys is hitting a fraction of that. The drugs suppress appetite so effectively that many patients stop thinking about nutrition quality altogether — and the muscle loss follows.

Strategies for both drugs:

• Eat protein first at every meal. Even with suppressed appetite, hitting protein before carbohydrates or fat protects muscle while still allowing total intake to be low.
• Use calorie-dense, protein-rich foods. Greek yogurt (17g/cup), cottage cheese (25g/cup), eggs (6g each), rotisserie chicken — foods that deliver protein without requiring large volumes.
• Treat protein shakes as insurance. On days when appetite nearly disappears, 20–25g from a protein shake before dropping the meal matters.

Neither Ozempic nor Mounjaro improves the protein equation on its own. That gap requires active management.

Resistance Training: The Same Answer for Both Drugs

The evidence for resistance training as the primary lever for preserving lean mass is consistent across drug types. A 2025 meta-analysis of 62 randomized controlled trials found resistance training reduced caloric restriction-induced lean mass loss by approximately 93%.

The mechanism is simple: your muscles atrophy when they have no reason to exist. Heavy loaded movement gives them a reason. The caloric deficit from either semaglutide or tirzepatide does not change this equation.

Minimum evidence-supported protocol:

• 2–3 sessions per week
• Multi-joint compound movements (squats, rows, deadlifts, presses)
• Progressive overload — each week or two, make it harder

Both drugs can make this harder in the first 4–8 weeks due to fatigue and GI side effects. Reducing intensity temporarily is fine. Stopping is where the lean mass goes.

Tracking What Matters: Body Composition, Not Just Weight

If you’re comparing yourself on Ozempic versus a friend on Mounjaro, the scale gives you almost no useful information. Two people who’ve lost the same number of pounds may have wildly different body composition changes.

What to actually track:

• DEXA scan — the gold standard. Available at hospitals and many fitness centers for ~$50–150. Takes 10 minutes. Tells you exactly how much fat and lean mass you have and where it’s distributed.
• Bioelectrical impedance — consumer smart scales (Withings, Tanita, InBody kiosks). Less accurate than DEXA but directionally useful for tracking trends over months.
• Grip strength — a surprisingly well-validated proxy for overall muscle function and a predictor of long-term health outcomes. Test it with a dynamometer (~$30 on Amazon) or use a local gym’s equipment.
• Epigenetic age testing — measures how your biology is aging, not just how heavy you are. The TruDiagnostic TruAge PACE test can detect whether your interventions are slowing or accelerating biological aging.

Baseline testing before (or early in) your GLP-1 course gives you a reference point. Without it, you’re flying blind on the question that matters most: what kind of weight am I losing?

(Disclosure: TruDiagnostic links on this site may be affiliate links. This does not affect editorial independence — we only recommend tools we believe are scientifically credible.)

Research Peptides: What the Science Examines in This Context

Important framing: Research peptides are research chemicals, not FDA-approved drugs or supplements. This section describes what is being studied in scientific literature — not what is recommended for human use. Nothing here constitutes medical advice or a protocol recommendation.

With that clearly stated: the muscle-loss problem in GLP-1 therapy has attracted attention in the peptide research field, specifically around compounds studied for their roles in muscle biology and connective tissue repair.

Growth hormone secretagogues (CJC-1295 / Ipamorelin): These compounds have been studied in animal models and clinical research for their effects on growth hormone pulsatility, body composition, and sarcopenia — age-related muscle loss. The biological pathways they interact with (GHRH receptor and GHS-R1a) are relevant to muscle protein synthesis research. Published literature is searchable on PubMed. For a detailed breakdown of how these two compounds interact mechanistically, see CJC-1295 and Ipamorelin: What the Research Shows About GH Synergy.

BPC-157: A 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice. Animal model studies have investigated its effects on connective tissue repair, tendon healing, and gastrointestinal homeostasis. A scheduled FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23–24, 2026 will consider whether to recommend BPC-157 for the Section 503A positive bulks list — a meeting that has not yet occurred, with an unknown outcome.

Research-grade vendors exist for those conducting independent scientific investigations. These are study-use materials, not clinical therapies or supplements.

The Bottom Line

The clinical trial picture gives tirzepatide a modest edge on lean-mass preservation (25% of weight lost vs. ~40% with semaglutide). The real-world picture, from the largest study to date (670,000+ patients), shows the opposite — tirzepatide associated with 1–2% more lean mass loss than semaglutide by 12 months.

What that means practically:

1. There is no GLP-1 drug that protects your muscle. Whichever one your doctor prescribes, lean mass loss is a real risk without active mitigation.
2. The drug that drives more aggressive weight loss may also drive more aggressive muscle loss — especially if you don’t match appetite suppression with deliberate protein intake and resistance training.
3. The behaviors (protein + lifting) are the dominant variables — not the drug choice. A semaglutide user who lifts 3x/week and hits 1.6g/kg protein will likely preserve more muscle than a tirzepatide user who doesn’t.

Both drugs work. Both drugs can erode what you build over a lifetime. The research is clear enough on prevention that not acting on it is the real risk.